Journal of Clinical Oncology最新文献

{"title":"Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.","authors":"Erin M Mobley, David R Doody, Steven D Colan, Sanjeev Aggarwal, Richard Aplenc, Saro H Armenian, K Scott Baker, Smita Bhatia, Louis S Constine, David R Freyer, Lisa M Kopp, Wendy M Leisenring, Nao Sasaki, Lynda M Vrooman, Barbara L Asselin, Cindy L Schwartz, Eric J Chow, Steven E Lipshultz","doi":"10.1200/JCO-26-02036","DOIUrl":"10.1200/JCO-26-02036","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2756"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting ErbB-Family Receptors in Small Cell Lung Cancer: Clinical Activity and an Unresolved Mechanism.","authors":"Junko Tanizaki","doi":"10.1200/JCO-26-01469","DOIUrl":"10.1200/JCO-26-01469","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2653-2656"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.","authors":"Axel Hauschild, Jessica Cecile Hassel, Mirjana Ziemer, Piotr Rutkowski, Friedegund Meier, Lukas Flatz, Caroline Gaudy-Marqueste, Mario Santinami, Francesco Russano, Imke von Wasielewski, Thomas Eigentler, Michele Maio, Iris Zalaudek, Sebastian Haferkamp, Pietro Quaglino, Julia Welzel, Michael Weichenthal, Giuliano Elia, Alfredo Covelli, Katia Lorizzo, Agnese Parca, Dario Neri, Paolo Antonio Ascierto, Caroline Robert, Dirk Schadendorf, Katharina Charlotte Kaehler","doi":"10.1200/JCO-26-00852","DOIUrl":"10.1200/JCO-26-00852","url":null,"abstract":"<p><p>Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier: NCT02938299). The trial enrolled 256 patients in the European Union and met its primary end point, demonstrating a statistically significant improvement in recurrence-free survival (RFS; hazard ratio, 0.59; <i>P</i> = .005) for daromun followed by surgery versus up-front surgery, at a median follow-up (FU) of 21 months from random assignment. PIVOTAL included two clinically distinct subgroups, namely, patients with de novo diagnosed metastatic disease (n = 34; 13%) and patients with recurrence(s) after surgery with or without radiotherapy and/or adjuvant systemic therapies (n = 222; 87%). Here, we present an updated analysis of the primary and secondary end points, including safety data, at a median FU of 36.8 months from random assignment (database cutoff: November 28, 2025), alongside new sensitivity analyses of event-free survival (EFS). The updated analysis confirms the clinically and statistically meaningful improvements in RFS and distant metastasis-free survival recorded in the neoadjuvant daromun versus control arm. The EFS post hoc analysis, conducted in both the overall population and the recurrent patient subgroups (with or without prior systemic therapies), provides consistency and robustness to the benefit of neoadjuvant daromun observed for the primary efficacy end point. No new safety signals of concern were recorded.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2662-2669"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148712614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Patient Who Could Not Die.","authors":"Erika Ramsdale","doi":"10.1200/JCO-25-02505","DOIUrl":"10.1200/JCO-25-02505","url":null,"abstract":"<p><p>An oncologist meets a patient who was never born and would never die and considers what AI can (and can't) teach about the art of connection.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2745-2747"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.","authors":"Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang","doi":"10.1200/JCO-26-00243","DOIUrl":"10.1200/JCO-26-00243","url":null,"abstract":"<p><strong>Purpose: </strong>Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited treatment options beyond frontline chemo-immunotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) is a first-in-class bispecific antibody-drug conjugate cotargeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). We expanded the SCLC cohort to further evaluate the efficacy and safety of iza-bren in patients with extensive-stage SCLC (ES-SCLC).</p><p><strong>Methods: </strong>This open-label, multicenter, dose-expansion phase Ib study (ClinicalTrials.gov identifier: NCT05194982) enrolled patients with ES-SCLC who had progressed on prior systemic therapies. Patients received iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle. The primary end points were objective response rate (ORR) and safety/tolerability. Secondary end points included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory end point included the assessment of potential associations between EGFR/HER3 expression and clinical outcomes.</p><p><strong>Results: </strong>As of December 5, 2024, 52 patients were enrolled. The ORR was 48.1% (95% CI, 34.0 to 62.4), with a median PFS of 4.1 months (95% CI, 3.0 to 5.5) and a median OS of 12.2 months (95% CI, 9.1 to 13.2). In patients who received iza-bren as second-line treatment (n = 22), the ORR was 72.7% (95% CI, 49.8 to 89.3), median PFS 6.2 months (95% CI, 3.7 to 8.2), and median OS 15.0 months (95% CI, 8.7 to not reached). The most common treatment-related adverse events were hematologic toxicities (neutropenia, thrombocytopenia, anemia, and leukopenia). Exploratory biomarker analysis suggested that positive HER3 expression may be associated with better treatment response.</p><p><strong>Conclusion: </strong>Iza-bren showed encouraging antitumor activity in relapsed ES-SCLC, particularly in the second-line setting. A phase III randomized controlled trial of iza-bren compared with topotecan (ClinicalTrials.gov identifier: NCT06500026) is ongoing.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2670-2679"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.","authors":"Othman Al-Sawaf, Can Zhang, Mohammad S Esfahani, Chih Long Liu, Sandra Robrecht, Eugen Tausch, Anke Schilhabel, Matthias Ritgen, Christof Schneider, Martin Peifer, Moritz Fürstenau, Carsten Utoft Niemann, Arnon P Kater, John F Seymour, Brenda Chyla, Yanwen Jiang, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Ash A Alizadeh, David M Kurtz, Kirsten Fischer","doi":"10.1200/JCO-26-00161","DOIUrl":"10.1200/JCO-26-00161","url":null,"abstract":"<p><strong>Purpose: </strong>Measurable residual disease (MRD) status after limited-duration treatment for chronic lymphocytic leukemia (CLL) strongly predicts survival times and is considered a surrogate end point. However, most prognostic indices, including the International Prognostic Index (CLL-IPI), rely solely on pretreatment features. To incorporate dynamic MRD data in prognostic models, the continuous individualized risk index (CIRI) was proposed in 2019. Since developed in the context of chemoimmunotherapy, we here propose a refined version of CIRI, in the context of fixed-duration targeted therapy, which includes MRD status at interim, end-of-treatment (EoT) and, in addition, 12-month post-EoT (CIRI2-CLL).</p><p><strong>Methods: </strong>After developing model parameters from the CLL8/10/11 and MURANO trials, we applied CIRI2-CLL to independent validation sets from the CLL14 (venetoclax-obinutuzumab <i>v</i> chlorambucil-obinutuzumab) and CLL13 (venetoclax-obinutuzumab with or without ibrutinib <i>v</i> chemoimmunotherapy) trials and assessed model calibration, stratification, and performance.</p><p><strong>Results: </strong>We compared CIRI2-CLL with individual indices and found good calibration with an approximately 5% difference between observed and predicted event probabilities for progression-free survival (PFS). CIRI2-CLL demonstrated superior performance compared with individual indices as measured by C-statistics between 0.82 and 0.98 at all time points, including MRD and CLL-IPI, improving PFS prediction by 14%-37% from 2 to 5 years. When stratifying patients by CIRI2-CLL into low-, intermediate-, and high-risk groups, the corresponding 3-year PFS rates were 100.0%, 70.2%, and 10.8%. Performance was maintained for overall survival.</p><p><strong>Conclusion: </strong>These results validate CIRI2-CLL in the context of limited-duration CLL therapy. Our approach suggests the models' adaptability to emerging additional longitudinal MRD and/or outcome data. By introducing CIRI2-CLL, we offer a dynamic tool for investigators to reliably identify patients with increased risk of disease relapse after limited-duration therapy with venetoclax and obinutuzumab, freely accessible at CIRI2 (Stanford University), with important implications for informed decision making and for future risk-adapted CLL trial design.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2700-2713"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.","authors":"Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, Hossein Borghaei, D Ross Camidge, Konstantin H Dragnev, Martin J Edelman, David R Gandara, David E Gerber, Jhanelle E Gray, Fred R Hirsch, Hatim Husain, David E Kozono, Natasha B Leighl, Bob T Li, Tianhong Li, Philip C Mack, Joel W Neal, Paul K Paik, Sandip P Patel, Jonathan W Riess, Mary W Redman, Karen L Reckamp","doi":"10.1200/JCO-25-01896","DOIUrl":"10.1200/JCO-25-01896","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2657-2661"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.","authors":"Dan-Yun Ruan, Feng-Hua Wang, Yujuan Zhou, Yanqun Xiang, Jinguan Lin, Lin Liu, Ping Liu, Linquan Tang, Yuxiang Ma, Tao Hou, Qiuyan Chen, Zhi-Ming Li, Fei Han, Song Qu, Sufang Qiu, Chen Han, Hongzhi Ma, Fang Su, Jin Gao, Ye Guo, Zheng Wu, Hai-Jun Wu, Yanqiu Zhao, Meiyu Fang, Man Hu, Yuan Wu, Shuo Cui, Mengyun Li, Qiong Zhao, Rui-Hua Xu","doi":"10.1200/JCO-26-00640","DOIUrl":"10.1200/JCO-26-00640","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti-PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combined with a PD-1 inhibitor pucotenlimab in this setting of patients.</p><p><strong>Materials and methods: </strong>Magic-C001 (ClinicalTrials.gov identifier: NCT05688605) is an ongoing, open-label, multicohort, dose escalation (phase I) and expansion (phase II) study in patients with EGFR-positive solid tumors. Eligible patients received pucotenlimab 3.0 mg/kg and BV at 1.8-2.3 mg/kg (phase I) or 2.0 mg/kg (phase II for NPC) once every 3 weeks. The primary end point for phase II was objective response rate (ORR). Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.</p><p><strong>Results: </strong>Among 31 patients with NPC at the recommended phase II dose (RP2D) from phase I and II who had received anti-PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0 to 85.8); DCR was 93.5% (95% CI, 78.6 to 99.2). The median DoR and PFS were 14.0 months (95% CI, 5.7 to not estimated) and 12.0 months (95% CI, 6.8 to 15.4), respectively. Median OS was not mature. Most common treatment-related adverse events (TRAEs) were pruritus (71.9%), hypoesthesia (65.6%), anemia (59.4%), and rash (56.3%). TRAEs of ≥grade 3 occurred in 40.6% of patients. No TRAEs led to death.</p><p><strong>Conclusion: </strong>To our knowledge, we report the first trial combining an ADC with immunotherapy for platinum and anti-PD-1/PD-L1-resistant NPC. BV plus pucotenlimab yielded a notable ORR with exceptionally durable responses and substantially prolonged PFS, alongside manageable toxicities. This regimen may offer a promising anti-PD-1 rechallenge strategy in this population, which is being confirmed in an ongoing, multicenter, randomized controlled, phase III study.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2690-2699"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.","authors":"Erin M Mobley, David R Doody, Steven D Colan, Sanjeev Aggarwal, Richard Aplenc, Saro H Armenian, K Scott Baker, Smita Bhatia, Louis S Constine, David R Freyer, Lisa M Kopp, Wendy M Leisenring, Nao Sasaki, Lynda M Vrooman, Barbara L Asselin, Cindy L Schwartz, Eric J Chow, Steven E Lipshultz","doi":"10.1200/JCO-26-00260","DOIUrl":"10.1200/JCO-26-00260","url":null,"abstract":"<p><strong>Purpose: </strong>Dexrazoxane has been associated with preservation of left ventricular (LV) systolic function in relatively small studies of long-term childhood cancer survivors. What remains less clear is whether this association is also seen in larger populations over time and what effect dexrazoxane has on cardiomyopathy screening recommendations.</p><p><strong>Methods: </strong>We analyzed echocardiographic data from participants who received doxorubicin treatment and were enrolled on Children's Oncology Group protocols P9404, P9425, P9426, P9754, and Dana Farber Cancer Institute protocol 95-01. Except for P9754, all protocols featured up-front 1:1 random assignment with dexrazoxane administered uniformly as an intravenous bolus before doxorubicin (10:1 mg/m² dexrazoxane:doxorubicin dose). Blinded central echocardiogram remeasurements were used when possible; otherwise, data were abstracted from institutional reports. Differences and associations by ± dexrazoxane were estimated using generalized estimating equations and Cox proportional hazard models, adjusting for age, sex, doxorubicin dose, chest radiotherapy, and echocardiogram data type.</p><p><strong>Results: </strong>Among 895 patients (mean follow-up, 5.9 years, 230 with ≥10-year follow-up; median doxorubicin dose, 360 mg/m²; 51% dexrazoxane-exposed) with evaluable echocardiograms (n = 2,279; 1,581 centrally remeasured; 698 report only), preserved LV systolic function was observed in patients treated with dexrazoxane (z-score difference 0.4 [95% CI, 0.2 to 0.5]) versus without. Dexrazoxane was also associated with decreased hazards of reduced LV function (fractional shortening <30% or ejection fraction <50%) occurring after 1 (0.58 [95% CI, 0.41 to 0.82]) and 5 years (0.54 [95% CI, 0.31 to 0.93]) postdiagnosis. Finally, dexrazoxane appeared to decrease the incidence of reduced LV function among those classified by current cardiomyopathy screening guidelines as high risk to rates like a lower-risk group (from 40 to 21.8 events/1,000 person-years; <i>P</i> = .001).</p><p><strong>Conclusion: </strong>Dexrazoxane exerts a significant doxorubicin cardioprotective effect on LV systolic function long term and may reduce screening needs.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2680-2689"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148684909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.","authors":"Mathias Castonguay, John F Seymour","doi":"10.1200/JCO-26-00428","DOIUrl":"10.1200/JCO-26-00428","url":null,"abstract":"<p><p>Relapsed or refractory (RR) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presents increasing therapeutic complexity in the era of targeted agents. Frontline use of covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax-based fixed-duration (FD) or minimal residual disease-guided regimens has led to deeper remissions, yet many patients will eventually require subsequent therapy. Management of first relapse should integrate clinical status, prior therapy, progression kinetics, and assessment for Richter transformation, along with genomic re-evaluation (particularly acquired resistance mutations and <i>TP53</i> aberrations).Multiple effective options exist for relapsing disease. Second-generation cBTKi (acalabrutinib, zanubrutinib) continuous therapy provides durable disease control with improved tolerability over ibrutinib, whereas continuous venetoclax monotherapy or FD venetoclax-rituximab achieves high response rates and prolonged remission, with retreatment feasible for selected patients. Noncovalent BTKis (ncBTKis) such as pirtobrutinib offer meaningful activity in patients previously exposed to cBTKi. Cellular therapies, particularly lisocabtagene maraleucel, have demonstrated substantial efficacy in heavily pretreated patients, and allogeneic hematopoietic cell transplantation remains an option for select individuals with double-class refractory disease. Emerging therapies-including BTK degraders, next-generation BCL2 inhibitors, and bispecific antibodies-will likely reshape the therapeutic landscape for RR CLL/SLL. With broadening treatment options for RR CLL/SLL, optimal sequencing requires consideration of disease biology, depth and duration of prior response, comorbidities, toxicity profiles, patient preferences, and logistical factors. As therapeutic options expand, individualized treatment planning and clinical trial participation remain essential for improving outcomes in RR CLL/SLL.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2714-2724"},"PeriodicalIF":44.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}